Mirvie Raises $60M in Series B Funding
The company plans to use the funding to propel the clinical and commercial development of its Mirvie RNA testing platform for pregnancy health.
The South San Francisco-based startup recently published two studies showing the performance of its tests for predicting preterm birth and preeclampsia.
Maternal Cell-Free RNA Can Gauge Preeclampsia Risk Months Before Symptoms, Study Finds
Researchers from startup Mirvie and elsewhere reported that cfRNA profiles of pregnant women can predict who may later develop preeclampsia.
Progenity to Close Genetics Lab as Focus Shifts to Therapeutics
The firm will no longer offer its Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, or Resura Prenatal Test.
Progenity Q4 Revenues Fall 30 Percent on COVID-19 Effect
The firm's revenue decrease was largely driven by a decline in testing volumes due to the COVID-19 pandemic, it said.